Zacks.com on MSN8h
Merck Q4 Earnings Coming Up: Buy, Hold or Sell MRK Stock Now?
Merck MRK will report its fourth-quarter and full-year 2024 earnings on Feb. 4, before market open. The Zacks Consensus ...
pharmaphorum22h
FDA says yes to MSD’s 21-valent adult pneumococcal jab
The rivalry between Pfizer and MSD in pneumococcal vaccines has dialled up a notch with the FDA approval of MSD’s new shot Capvaxive, the first to be aimed specifically at adults. The 21-valent ...
pharmaphorum4d
Vaxcyte's pneumococcal vaccine win points to Prevnar battle
In June, MSD got FDA approval for a 21-valent vaccine, called Capvaxive, which is the first jab approved for the over-50s category. At the moment, pneumococcal vaccination is recommended for the ...
clinicalpainadvisor.com4d
2024 Novel Drug and Biological Product Approvals
The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.